RNPA1000

RNPA1000, an antibiotic, is a potent RnpA inhibitor and inhibits RnpA-mediated cellular RNA degradation. RNPA1000 inhibits tRNA maturation with an IC50 of 175 μM. RNPA1000 displays broad-spectrum antimicrobial activities and inhibits staphylococcal and all Gram-positive bacterial pathogens activity[1][2][3].

Product Specifications

CAS Number

[359600-10-5]

UNSPSC

12352005

Target

Antibiotic; Bacterial

Type

Reference compound

Related Pathways

Anti-infection

Applications

Neuroscience-Neuromodulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/RNPA1000.html

Concentration

10mM

Purity

98.16

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C(O)C1=CC=C(N2C(C)=C(/C=C(C#N)/C(NC3=CC=CC(Br)=C3)=O)C=C2C)C=C1

Molecular Formula

C23H18BrN3O3

Molecular Weight

464.31

References & Citations

[1]Eidem TM, et al. Drug-eluting cements for hard tissue repair: a comparative study using vancomycin and RNPA1000 to inhibit growth of Staphylococcus aureus. J Biomater Appl. 2014 Apr;28 (8) :1235-46.|[2]Eidem TM, et al. Small-molecule inhibitors of Staphylococcus aureus RnpA-mediated RNA turnover and tRNA processing. Antimicrob Agents Chemother. 2015 Apr;59 (4) :2016-28.|[3]Patrick D Olson, et al. Small molecule inhibitors of Staphylococcus aureus RnpA alter cellular mRNA turnover, exhibit antimicrobial activity, and attenuate pathogenesis. PLoS Pathog. 2011 Feb 10;7 (2) :e1001287.